strategic partners, and industry leaders actively looking for new technologies.
Applications are still open to present at LSI Asia ‘26.
-(11)-medium.webp)
_-_2026-03-18T105404.171-small.webp){kind=small}
-(12)-medium.webp)
_-_2026-03-18T104655.620-small.webp){kind=small}
Pioneering Endoscopic Metabolic Restoration for Type 2 Diabetes through Aqua Medical’s proprietary RF Vapor Ablation (RFVA) platform. Aqua Medical has developed a through-the-scope, fluoroscopy-free technology designed to ablate targeted gastrointestinal tissue using heated water vapor delivered via endoscopic catheters. The Aqua procedure has demonstrated some exciting early results, including lowering hemoglobin A1c, as well as eliminating insulin dependency in certain cohorts of patients.
-(13)-medium.webp)
_(2)-small.webp){kind=small}
ArthroLase is an Australian medical device company developing an intelligent robotic laser bone shaping system for knee replacement and resurfacing surgery. Its two core platforms, HAiLO and AIRO-x, integrate non-contact high-speed laser bone cutting with surgical robotics, real-time intraoperative 3D digital sensing, and intelligent computer control to achieve sub-millimetre precision in osteotomy procedures.
_(4)-small.webp){kind=small}
BIOCAPTIVA develops msX™, a proprietary polymer-based platform that directly captures cell-free DNA and RNA from biological fluids, addressing the most critical bottleneck in liquid biopsy: pre-analytics. By enabling high-yield, low-contamination nucleic acid capture directly from whole blood and other biofluids, msX™ simplifies workflows, improves sensitivity, and is fully compatible with automation and OEM integration.
_(12)-small.webp){kind=small}
CardioStory is a clinical-stage medical technology company developing a Non-Invasive Filling Pressure (NIFP) measurement device for Heart Failure (HF) patients. The system utilizes proprietary fiber optic sensors and advanced algorithms to capture microscopic chest vibrations and accurately calculate pressure inside the heart in just two minutes. Differentiated by its ability to replace highly invasive catheters and surgical implants with a simple, non-invasive assessment, CardioStory aims to empower proactive heart failure management and significantly reduce costly hospital readmissions.
ComplyWise is a real-time healthcare data validation platform that analyzes clinical and claims data against compliance rules to improve clinical workflows and proactively identify potential compliance and data quality issues.
-(22)-medium.webp)
_(10)-small.webp){kind=small}
-(14)-medium.webp)
_-_2026-03-24T073034.638-small.webp){kind=small}
CoreMotion is developing the PeriK System, a quantitative pelvic floor assessment and rehabilitation solution designed to measure pelvic floor function and enable data-driven, personalized therapy.
_-_2026-03-24T072105.414-small.webp){kind=small}
Cytophenix Pty Ltd is an early-stage medical diagnostics company developing FloCAST, an AI-powered platform for rapid Antimicrobial Susceptibility Testing (AST). The technology uses flow cytometry and machine learning to analyze how individual bacterial and fungal cells respond to antibiotics in real-time, delivering targeted treatment recommendations in three to four hours rather than days. Differentiated by its speed, single-cell resolution, and seamless laboratory integration, Cytophenix empowers doctors to treat sepsis more effectively, saving lives while combating global antibiotic resistance.
_(11)-small.webp){kind=small}
Ferronova's lead product, FerroTrace, is a magnetic nanoparticle tracer injected around a primary tumour prior to surgery. The nanoparticles follow the body's natural lymphatic pathways — the same routes through which cancer spreads — allowing surgeons to intraoperatively identify high risk lymph nodes with accompanying surgical devices. The novel FerroTrace formulation is designed to be retained in lymph nodes for >6 months, overcoming the major problem with other "tracers" which are ineffective after pre-surgical neoadjuvant treatment.
_(34)-small.webp){kind=small}
_-_2026-03-18T104835.437-small.webp){kind=small}
Gyder Surgical's Gyder Hip System is a non-invasive, pin-less navigation solution for total hip replacement. The system is an open platform that can be used with a surgeon's preferred implant system, reduces radiation exposure by not requiring CT or X-ray imaging, and seamlessly integrates into existing workflows due to the system's simple set-up and quick calibration.
-(15)-medium.webp)
-(16)-medium.webp)
Hygea, as the No.1 Chinese Co-ablation developer had developed a strong pipeline in minimally Invasive Oncology area including 85℃/-196℃ Co-Ablation(FDA/CE/CFDA), Irreversible Electroporation(IRE), Microwave Ablation (MWA, FDA/CE/CFDA) systems and TACE Biodegradable Microspheres, based on its percutaneous ablation and Endovascular intervention platforms. More than 30K+ patients globally benefit from company’s innovation since its 1st Co-ablation system launched in 2017.
_(80)-small.webp){kind=small}
Innovate Medtech is a medical device innovation studio that develops core technology for Class II and III devices. Capabilities include advanced materials (hydrogel membranes, flexible electronics, sensors, electrochemical biosensors and IVDs), prototyping, design control, IP strategy, and regulatory pathway planning. Beyond technology development, the company works closely with founders to help build both the product and the company around it, supporting the journey from early concept through to commercialisation and scale-up.
We seek partners to explore moving existing lab-based testing into point of care settings. This will give first mover advantage to many companies seeking to gain competitive USPs for existing product lines.
_(68)-small.webp){kind=small}
LyzeData is a data intelligence platform focused on KPI definition and computation across heterogeneous data sources. It combines automated data ingestion, normalization, and validation to produce reliable, decision-ready metrics with minimal configuration.
_(12)-small.webp){kind=small}
Materia Health is an early-stage medical technology company offering the MateriaPOD, a smart, portable preservation platform designed to replace legacy ice-based storage for donor organs, tissues, and blood products. The technology utilizes active, software-driven temperature control and internal pressure cushioning to maximize cellular viability and reduce transplant complications. Differentiated by its robust, multi-application architecture, Materia Health is optimizing its reusable capsule to solve critical biological logistics challenges in human healthcare, defense trauma care, and veterinary science.
_(13)-small.webp){kind=small}
-(17)-medium.webp)
Navier Medical offers Mosaic, an FDA-cleared, AI-driven software platform for the advanced evaluation of cardiovascular disease from standard CT angiography scans. The technology provides comprehensive 3D visualization and quantifies high-risk arterial plaque burden, allowing clinicians to detect hidden disease often missed by routine assessments. Differentiated by its ability to uncover deep, patient-specific cardiovascular risks without altering the standard imaging workflow, Navier Medical aims to prevent severe cardiac events through earlier, more personalized intervention.
-(18)-medium.webp)
-(19)-medium.webp)
_-_2026-03-18T093309.787-small.webp){kind=small}
-(20)-medium.webp)
SeeTreat Medical is a software company developing ART.1, an automated decision-support platform for adaptive radiotherapy. The Software as a Medical Device (SaMD) continuously analyzes daily volumetric imaging to track anatomical changes and calculate delivered radiation doses, instantly alerting clinical teams if a patient's treatment plan needs adjustment. Differentiated by its ability to integrate seamlessly with existing linear accelerators without requiring hardware upgrades, SeeTreat enables oncology clinics to efficiently provide personalized, precision cancer treatments.
_-_2026-03-24T070806.954-small.webp){kind=small}
SiBionics is a commercial-stage medical device company offering the GS1 Continuous Glucose Monitoring (CGM) System, a calibration-free, 14-day wearable sensor for diabetes care. The technology uses an integrated electrochemical sensor to provide real-time glucose readings every five minutes directly to a smartphone. Differentiated by its high clinical accuracy (8.83% MARD), waterproof design, and user-friendly "all-in-one" form factor, SiBionics provides a seamless, data-driven alternative to traditional blood glucose monitoring for millions of users worldwide.
Spirecut AG is a commercial-stage, ISO 13485-certified Swiss medical device company revolutionizing surgery with patented, incisionless surgical instruments. Spirecut’s solution is a game changer for the healthcare system, enabling a shift from expensive operating rooms to cost-effective office-based surgery, while offering patients scar-free healing and immediate return to daily activities. The first applications are carpal tunnel and trigger finger surgery, affecting one person on seven. Spirecut patented instruments are CE-marked and the company is FDA-listed. Spirecut successfully launched market in 2024, selling more than 6’000 kits for over CHF 1Mn in revenue. Spirecut has eight publications in peer-reviewed medical journals. Spirecut, with subsidiaries in Belgium, USA and Hong Kong, has raised CHF 2.5M from private investors. The current round (series A) of CHF 10 Mn (equity) is needed for scale and R/D, as Spirecut ambitions to become the global leader of ultra- minimally invasive surgery (sonography-guided, incisionless). Exit in 2031 as IPO.
-(21)-medium.webp)
_-_2026-03-19T091121.521-small.webp){kind=small}
Tensor Surgical develops technologies for orthopedic soft tissue repair sports medicine. The company’s portfolio of products consists of solutions to simplify and reduce the cost rotator cuff repair and bicep tenodesis procedures.
_(4)-small.webp){kind=small}
Pioneers of radar based, ambient health monitoring. Their XK300 sensor is FDA cleared in 6 countries, including the U.S. where they collected 2,750 years' worth of data from 44,000 unique patients to date. Equipped with unique biometric data from patterns of vibrations (breathing/heart), the company was able to create AI models that accurately predicted UTI, Heart Failure, COVID, COPD and even death at 74%~89% accuracy, 4-6 days prior to an event.
-(11)-small.webp)
-(12)-small.webp)
-(13)-small.webp)
Pioneering Endoscopic Metabolic Restoration for Type 2 Diabetes through Aqua Medical’s proprietary RF Vapor Ablation (RFVA) platform. Aqua Medical has developed a through-the-scope, fluoroscopy-free technology designed to ablate targeted gastrointestinal tissue using heated water vapor delivered via endoscopic catheters. The Aqua procedure has demonstrated some exciting early results, including lowering hemoglobin A1c, as well as eliminating insulin dependency in certain cohorts of patients.
ArthroLase is an Australian medical device company developing an intelligent robotic laser bone shaping system for knee replacement and resurfacing surgery. Its two core platforms, HAiLO and AIRO-x, integrate non-contact high-speed laser bone cutting with surgical robotics, real-time intraoperative 3D digital sensing, and intelligent computer control to achieve sub-millimetre precision in osteotomy procedures.
BIOCAPTIVA develops msX™, a proprietary polymer-based platform that directly captures cell-free DNA and RNA from biological fluids, addressing the most critical bottleneck in liquid biopsy: pre-analytics. By enabling high-yield, low-contamination nucleic acid capture directly from whole blood and other biofluids, msX™ simplifies workflows, improves sensitivity, and is fully compatible with automation and OEM integration.
-(22)-small.webp)
CardioStory is a clinical-stage medical technology company developing a Non-Invasive Filling Pressure (NIFP) measurement device for Heart Failure (HF) patients. The system utilizes proprietary fiber optic sensors and advanced algorithms to capture microscopic chest vibrations and accurately calculate pressure inside the heart in just two minutes. Differentiated by its ability to replace highly invasive catheters and surgical implants with a simple, non-invasive assessment, CardioStory aims to empower proactive heart failure management and significantly reduce costly hospital readmissions.
ComplyWise is a real-time healthcare data validation platform that analyzes clinical and claims data against compliance rules to improve clinical workflows and proactively identify potential compliance and data quality issues.
-(14)-small.webp)
CoreMotion is developing the PeriK System, a quantitative pelvic floor assessment and rehabilitation solution designed to measure pelvic floor function and enable data-driven, personalized therapy.
Cytophenix Pty Ltd is an early-stage medical diagnostics company developing FloCAST, an AI-powered platform for rapid Antimicrobial Susceptibility Testing (AST). The technology uses flow cytometry and machine learning to analyze how individual bacterial and fungal cells respond to antibiotics in real-time, delivering targeted treatment recommendations in three to four hours rather than days. Differentiated by its speed, single-cell resolution, and seamless laboratory integration, Cytophenix empowers doctors to treat sepsis more effectively, saving lives while combating global antibiotic resistance.
-(15)-small.webp)
Ferronova's lead product, FerroTrace, is a magnetic nanoparticle tracer injected around a primary tumour prior to surgery. The nanoparticles follow the body's natural lymphatic pathways — the same routes through which cancer spreads — allowing surgeons to intraoperatively identify high risk lymph nodes with accompanying surgical devices. The novel FerroTrace formulation is designed to be retained in lymph nodes for >6 months, overcoming the major problem with other "tracers" which are ineffective after pre-surgical neoadjuvant treatment.
Gyder Surgical's Gyder Hip System is a non-invasive, pin-less navigation solution for total hip replacement. The system is an open platform that can be used with a surgeon's preferred implant system, reduces radiation exposure by not requiring CT or X-ray imaging, and seamlessly integrates into existing workflows due to the system's simple set-up and quick calibration.
-(16)-small.webp)
Hygea, as the No.1 Chinese Co-ablation developer had developed a strong pipeline in minimally Invasive Oncology area including 85℃/-196℃ Co-Ablation(FDA/CE/CFDA), Irreversible Electroporation(IRE), Microwave Ablation (MWA, FDA/CE/CFDA) systems and TACE Biodegradable Microspheres, based on its percutaneous ablation and Endovascular intervention platforms. More than 30K+ patients globally benefit from company’s innovation since its 1st Co-ablation system launched in 2017.
Innovate Medtech is a medical device innovation studio that develops core technology for Class II and III devices. Capabilities include advanced materials (hydrogel membranes, flexible electronics, sensors, electrochemical biosensors and IVDs), prototyping, design control, IP strategy, and regulatory pathway planning. Beyond technology development, the company works closely with founders to help build both the product and the company around it, supporting the journey from early concept through to commercialisation and scale-up.
We seek partners to explore moving existing lab-based testing into point of care settings. This will give first mover advantage to many companies seeking to gain competitive USPs for existing product lines.
LyzeData is a data intelligence platform focused on KPI definition and computation across heterogeneous data sources. It combines automated data ingestion, normalization, and validation to produce reliable, decision-ready metrics with minimal configuration.
Materia Health is an early-stage medical technology company offering the MateriaPOD, a smart, portable preservation platform designed to replace legacy ice-based storage for donor organs, tissues, and blood products. The technology utilizes active, software-driven temperature control and internal pressure cushioning to maximize cellular viability and reduce transplant complications. Differentiated by its robust, multi-application architecture, Materia Health is optimizing its reusable capsule to solve critical biological logistics challenges in human healthcare, defense trauma care, and veterinary science.
-(17)-small.webp)
Navier Medical offers Mosaic, an FDA-cleared, AI-driven software platform for the advanced evaluation of cardiovascular disease from standard CT angiography scans. The technology provides comprehensive 3D visualization and quantifies high-risk arterial plaque burden, allowing clinicians to detect hidden disease often missed by routine assessments. Differentiated by its ability to uncover deep, patient-specific cardiovascular risks without altering the standard imaging workflow, Navier Medical aims to prevent severe cardiac events through earlier, more personalized intervention.
-(18)-small.webp)
-(19)-small.webp)
-(20)-small.webp)
SeeTreat Medical is a software company developing ART.1, an automated decision-support platform for adaptive radiotherapy. The Software as a Medical Device (SaMD) continuously analyzes daily volumetric imaging to track anatomical changes and calculate delivered radiation doses, instantly alerting clinical teams if a patient's treatment plan needs adjustment. Differentiated by its ability to integrate seamlessly with existing linear accelerators without requiring hardware upgrades, SeeTreat enables oncology clinics to efficiently provide personalized, precision cancer treatments.
SiBionics is a commercial-stage medical device company offering the GS1 Continuous Glucose Monitoring (CGM) System, a calibration-free, 14-day wearable sensor for diabetes care. The technology uses an integrated electrochemical sensor to provide real-time glucose readings every five minutes directly to a smartphone. Differentiated by its high clinical accuracy (8.83% MARD), waterproof design, and user-friendly "all-in-one" form factor, SiBionics provides a seamless, data-driven alternative to traditional blood glucose monitoring for millions of users worldwide.
-(21)-small.webp)
Spirecut AG is a commercial-stage, ISO 13485-certified Swiss medical device company revolutionizing surgery with patented, incisionless surgical instruments. Spirecut’s solution is a game changer for the healthcare system, enabling a shift from expensive operating rooms to cost-effective office-based surgery, while offering patients scar-free healing and immediate return to daily activities. The first applications are carpal tunnel and trigger finger surgery, affecting one person on seven. Spirecut patented instruments are CE-marked and the company is FDA-listed. Spirecut successfully launched market in 2024, selling more than 6’000 kits for over CHF 1Mn in revenue. Spirecut has eight publications in peer-reviewed medical journals. Spirecut, with subsidiaries in Belgium, USA and Hong Kong, has raised CHF 2.5M from private investors. The current round (series A) of CHF 10 Mn (equity) is needed for scale and R/D, as Spirecut ambitions to become the global leader of ultra- minimally invasive surgery (sonography-guided, incisionless). Exit in 2031 as IPO.
Tensor Surgical develops technologies for orthopedic soft tissue repair sports medicine. The company’s portfolio of products consists of solutions to simplify and reduce the cost rotator cuff repair and bicep tenodesis procedures.
Pioneers of radar based, ambient health monitoring. Their XK300 sensor is FDA cleared in 6 countries, including the U.S. where they collected 2,750 years' worth of data from 44,000 unique patients to date. Equipped with unique biometric data from patterns of vibrations (breathing/heart), the company was able to create AI models that accurately predicted UTI, Heart Failure, COVID, COPD and even death at 74%~89% accuracy, 4-6 days prior to an event.
Want to present at
LSI Asia ‘26?
story on our stage, connect with investors, and generate excitement
beyond the event with our digital media.
© 2026 Life Science Intelligence, Inc., All Rights Reserved. | Privacy Policy
